CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the following upcoming investor conferences:
William Blair 37th Annual Growth Stock Conference
Date: Tuesday, June 13, 2017
Time: 12:50 PM CT (1:50 PM ET)
Location: Chicago, IL
Goldman Sachs 38th Annual Global Healthcare Conference
Date: Tuesday, June 13, 2017
Time: 2:40 PM PT (5:40 PM ET)
Location: Ranchos Palos Verdes, CA
Live webcasts of the presentations can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in mainland China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.
Investor/Media Contact
Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/5b27cff6-a30d-49e0-beba-8484b4cc215b?size=1)
Source:
BeiGene, LTD.